Inavolisib-Based Therapy for PIK3CA-Mutated Advanced Male Breast Cancer: A Cost-Effectiveness Analysis
Inavolisib-based therapy is not cost-effective for treating PIK3CA-mutated advanced male breast cancer at its current price. Significant price reductions or adjustments to value assessment frameworks are required to ensure equitable access for this underserved population.
Authors
- Shaohong Luo (ORCID: https://orcid.org/0000-0003-0090-6374)
- Rongfang Lin
- Pinfang Huang
- S. Lin
- Xiaoting Huang
- Dayong Zeng
Institutions
- Fujian Medical University (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
Publication Details
- Journal
- Breast Cancer Targets and Therapy
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2147/bctt.s566088
- Primary Topic
- Male Breast Health Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fujian Medical University